Summary of Cytek Biosciences Q2 2026 Earnings Call

1Key Financial Results and Metrics

Revenue: Q2 2026 revenue was $48.1 million, a 6% increase year-over-year (from $45.6 million in Q2 2025).

Geographic Performance:

U.S.: Revenue of $28.2 million, up 18% year-over-year.

EMEA: Revenue of $11.3 million, down 8% year-over-year.

APAC (including China): Revenue of $7.9 million, flat year-over-year.

Product Revenue: $32.6 million, a 4% increase year-over-year, driven by high-end instruments.

Service Revenue: $15.6 million, up 10% year-over-year.

Gross Profit: GAAP gross profit of $28.3 million, with a gross margin of 59% (53% excluding a one-time $2.8 million tariff refund).

Net Loss: GAAP net loss of $12.2 million, compared to $5.6 million in Q2 2025.

Adjusted EBITDA: Loss of $1.5 million, down from a positive $1.3 million in Q2 2025.

Cash Position: Cash, cash equivalents, and marketable securities totaled $262 million as of June 30, 2026.

2Strategic Updates and Business Highlights

New Product Launches: Introduction of the Cytek Borealis, a 60-color, 7-laser flow cytometer, and an enhanced Aurora Evo with expanded automation capabilities.

Recurring Revenue Growth: Combined reagent and service revenue reached $18.5 million, up 8% year-over-year, now representing 35% of trailing 12-month revenue.

Installed Base Growth: Added 142 units in Q2, bringing the total to 3,933 units.

Organizational Update: Cytek will operate as three distinct business units starting Q3 2026: Solutions and Clinical, Research Technology, and Service.

3Forward Guidance and Outlook

Revenue Guidance: Full-year 2026 revenue guidance raised to $207 million to $212 million, reflecting positive trends in the U.S. and APAC markets.

Adjusted EBITDA: Expected to be around break-even for the full year, with improved performance anticipated in the second half of 2026.

4Bad News, Challenges, or Points of Concern

EMEA Performance: Continued budgetary pressures in EMEA led to an 8% revenue decline, with government R&D funding under pressure.

Increased Operating Expenses: Total operating expenses rose 15% year-over-year, driven by higher legal costs and personnel expenses.

Net Loss Increase: The net loss widened due to operational losses, lower net other income, and a tax expense compared to the prior year.

5Notable Q&A Insights

Market Dynamics: The U.S. market showed strong growth, particularly in academic and government sectors, while biopharma growth was flat. EMEA remains challenged due to shifting government priorities.

Replacement Market: Cytek is gaining market share as customers transition from conventional flow cytometers to full spectrum technology.

Clinical Market Strategy: Cytek aims to penetrate the clinical market, which is currently underdeveloped for them, by leveraging their approved clinical products and expanding their reagent offerings.

Reorganization Benefits: The restructuring into customer-aligned business units is expected to improve growth rates, although significant benefits may take time to materialize. Overall, Cytek Biosciences demonstrated solid revenue growth driven by the U.S. market and new product innovations, while facing challenges in EMEA and increasing operational costs. The company remains optimistic about future growth and market penetration strategies.